Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 13/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | ACLY | P53396 | 2/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5132135 | 0.94 | CCR1 (0.51) | CCR1CNR1 | |
| SCHEMBL3828071 | 0.88 | EPHX2 (0.44) | EPHX2CNR1ACLY | |
| SCHEMBL5131253 | 0.87 | CNR1 (0.40) | CCR1CNR1ACLY | |
| SCHEMBL5122673 | 0.83 | CCR1 (0.45) | CCR1EPHX2HSD11B1ACLYCHRM4 | |
| SCHEMBL5126115 | 0.83 | EPHX2 (0.43) | EPHX2CNR1ACLY | |
| SCHEMBL5126213 | 0.81 | OPRM1 (0.46) | CCR1 | |
| SCHEMBL5131580 | 0.80 | CCR1 (0.50) | CCR1CNR1 | |
| SCHEMBL494593 | 0.79 | CNR1 (0.50) | EPHX2CNR1ACLY | |
| SCHEMBL5122795 | 0.77 | SLC6A9 (0.42) | CCR1 | |
| SCHEMBL5128284 | 0.77 | CCR1 (0.48) | CCR1HSD11B1CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2086935-A1 | SUBSTITUTED SULFONAMIDE DERIVATIVES FOR USE AS BRADYKININ 1 RECEPTOR MODULATORS | Grünenthal GmbH (DE) | 2009-08-12 | — | — | EP | claimed |
| US-20080249128-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2008-10-09 | — | — | US | claimed |
| WO-2008046573-A1 | SUBSTITUTED SULFONAMIDE DERIVATIVES FOR USE AS BRADYKININ 1 RECEPTOR MODULATORS | Grünenthal GmbH (DE) | 2008-04-24 | — | — | WO | claimed |
| US-8580965-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2013-11-12 | — | — | US | disclosed |
| EP-2086935-A1 | SUBSTITUTED SULFONAMIDE DERIVATIVES FOR USE AS BRADYKININ 1 RECEPTOR MODULATORS | Grünenthal GmbH (DE) | 2009-08-12 | — | — | EP | disclosed |
| US-20080249128-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2008-10-09 | — | — | US | disclosed |
| WO-2008046573-A1 | SUBSTITUTED SULFONAMIDE DERIVATIVES FOR USE AS BRADYKININ 1 RECEPTOR MODULATORS | Grünenthal GmbH (DE) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249128-A1 | Substituted Sulfonamide Compounds | BDKRB1, BDKRB2, NPSR1 | CCR1 598/4885EPHX2 1287/4885HSD11B1 2319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.